CD8+ tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival.
Rosemary MillenShona HendryVignesh NarasimhanRebecca AbbottMatthew CroxfordPeter GibbsJeanne TieHui-Li WongIan JonesSuzanne KosmiderDavid ByrneJohn ZalcbergStephen FoxJayesh DesaiKumar VisvanathanRobert George RamsayBen TranPublished in: Clinical & translational immunology (2020)
In contrast to early-stage CRC, the immune response in primary tumors of patients with de novo mCRC does not appear to influence survival. A subgroup of MSS tumors was identified with increased TILs/PD-L1 comparable to MSI-H tumors, traditionally not be considered for immune checkpoint blockade and perhaps should be.